Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Obermayr E, Mohr T, Schuster E, Braicu EI, Taube E, Sehouli J, Vergote I, Pujade-Lauraine E, Ray-Coquard I, Harter P, Wimberger P, Joly-Lobbedez F, Mahner S, Moll UM, Concin N, Zeillinger R. Obermayr E, et al. Among authors: ray coquard i. Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978. Online ahead of print. Int J Cancer. 2024. PMID: 38676430
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.
Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Ray-Coquard I, et al. Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019. Front Oncol. 2019. PMID: 31552170 Free PMC article.
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. du Bois A, et al. Cancer. 2009 Mar 15;115(6):1234-44. doi: 10.1002/cncr.24149. Cancer. 2009. PMID: 19189349 Free article. Clinical Trial.
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Concin N, Ray-Coquard I, Glasspool RM, Braicu E, Farrelly L, Votan B, Mirza MR, Gonzalez Martin A, Vergote I, Pignata S. Concin N, et al. Int J Gynecol Cancer. 2020 Jun;30(6):730-734. doi: 10.1136/ijgc-2020-001464. Epub 2020 May 12. Int J Gynecol Cancer. 2020. PMID: 32404377 Free article. No abstract available.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Lorusso D, et al. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. Int J Gynecol Cancer. 2024. PMID: 38129136 Free PMC article. Clinical Trial.
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Callens C, et al. J Natl Cancer Inst. 2021 Jul 1;113(7):917-923. doi: 10.1093/jnci/djaa193. J Natl Cancer Inst. 2021. PMID: 33372675 Free PMC article. Clinical Trial.
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I. Sabatier R, et al. Eur J Cancer. 2023 Mar;181:42-52. doi: 10.1016/j.ejca.2022.11.029. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36634389 Free article.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
604 results